The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Petnidan     3-ethyl-3-methyl-pyrrolidine- 2,5-dione

Synonyms: Suksilep, Zarontin, Emeside, Ethymal, Suxilep, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Petnidan


Psychiatry related information on Petnidan


High impact information on Petnidan


Chemical compound and disease context of Petnidan


Biological context of Petnidan


Anatomical context of Petnidan


Associations of Petnidan with other chemical compounds


Gene context of Petnidan


Analytical, diagnostic and therapeutic context of Petnidan


  1. Glioblastoma induction after radiosurgery for meningioma. Yu, J.S., Yong, W.H., Wilson, D., Black, K.L. Lancet (2000) [Pubmed]
  2. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Coulter, D.A., Huguenard, J.R., Prince, D.A. Ann. Neurol. (1989) [Pubmed]
  3. Valproic acid and ethosuximide interaction. Mattson, R.H., Cramer, J.A. Ann. Neurol. (1980) [Pubmed]
  4. Absence seizures induce a decrease in cerebral blood flow: human and animal data. Nehlig, A., Vergnes, M., Waydelich, R., Hirsch, E., Charbonne, R., Marescaux, C., Seylaz, J. J. Cereb. Blood Flow Metab. (1996) [Pubmed]
  5. High-dose ethosuximide for epilepsy in Angelman syndrome: implication of GABA(A) receptor subunit. Sugiura, C., Ogura, K., Ueno, M., Toyoshima, M., Oka, A. Neurology (2001) [Pubmed]
  6. Ethosuximide in the treatment of absence (peptit mal) seizures. Browne, T.R., Dreifuss, F.E., Dyken, P.R., Goode, D.J., Penry, J.K., Porter, R.J., White, B.G., White, P.T. Neurology (1975) [Pubmed]
  7. 3,3-Dialkyl- and 3-alkyl-3-benzyl-substituted 2-pyrrolidinones: a new class of anticonvulsant agents. Reddy, P.A., Hsiang, B.C., Latifi, T.N., Hill, M.W., Woodward, K.E., Rothman, S.M., Ferrendelli, J.A., Covey, D.F. J. Med. Chem. (1996) [Pubmed]
  8. Comparison of the effects of anticonvulsant drugs with diverse mechanisms of action in the formalin test in rats. Shannon, H.E., Eberle, E.L., Peters, S.C. Neuropharmacology (2005) [Pubmed]
  9. Dyskinesia and akathisia induced by ethosuximide. Ehyai, A., Kilroy, A.W., Fenichel, G.M. Am. J. Dis. Child. (1978) [Pubmed]
  10. Effects of ethosuximide upon psychomotor responses and electromyographic parameters of healthy individuals. Kästner, I., Roth, N., Wagner, A. Acta Biol. Med. Ger. (1976) [Pubmed]
  11. On the action of the anti-absence drug ethosuximide in the rat and cat thalamus. Leresche, N., Parri, H.R., Erdemli, G., Guyon, A., Turner, J.P., Williams, S.R., Asprodini, E., Crunelli, V. J. Neurosci. (1998) [Pubmed]
  12. Computer model of ethosuximide's effect on a thalamic neuron. Lytton, W.W., Sejnowski, T.J. Ann. Neurol. (1992) [Pubmed]
  13. Ethosuximide kinetics: possible interaction with valproic acid. Bauer, L.A., Harris, C., Wilensky, A.J., Raisys, V.A., Levy, R.H. Clin. Pharmacol. Ther. (1982) [Pubmed]
  14. Antiabsence drugs and inhibitory pathways. Fromm, G.H., Glass, J.D., Chattha, A.S., Martinez, A.J., Silverman, M. Neurology (1980) [Pubmed]
  15. Valproic acid versus ethosuximide in the treatment of absence seizures. Sato, S., White, B.G., Penry, J.K., Dreifuss, F.E., Sackellares, J.C., Kupferberg, H.J. Neurology (1982) [Pubmed]
  16. Effects of valproate and ethosuximide on thalamocortical excitability. Nowack, W.J., Johnson, R.N., Englander, R.N., Hanna, G.R. Neurology (1979) [Pubmed]
  17. Synthesis and evaluation of N-(phenylacetyl)trifluoromethanesulfonamides as anticonvulsant agents. Flaherty, P.T., Greenwood, T.D., Manheim, A.L., Wolfe, J.F. J. Med. Chem. (1996) [Pubmed]
  18. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Davis, R., Peters, D.H., McTavish, D. Drugs (1994) [Pubmed]
  19. Effects of anticonvulsant drugs on substantia nigra pars reticulata neurons. Waszczak, B.L., Lee, E.K., Walters, J.R. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
  20. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Battino, D., Estienne, M., Avanzini, G. Clinical pharmacokinetics. (1995) [Pubmed]
  21. Valproate-induced biochemical abnormalities in pregnancy corrected by vitamins: a case report. Baggot, P.J., Kalamarides, J.A., Shoemaker, J.D. Epilepsia (1999) [Pubmed]
  22. Anticonvulsant drugs selectively affect kindled and penicillin epilepsy, especially during seizure-prone sleep or awakening states in cats. Shouse, M.N., Stroh, P.J., Vreeken, T. Epilepsia (1989) [Pubmed]
  23. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. McLean, M.J., Macdonald, R.L. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
  24. Effect of anticonvulsant drugs on gamma-hydroxybutyrate release from hippocampal slices: inhibition by valproate and ethosuximide. Vayer, P., Charlier, B., Mandel, P., Maitre, M. J. Neurochem. (1987) [Pubmed]
  25. gamma-Hydroxybutyric acid in subcellular fractions of rat brain. Snead, O.C. J. Neurochem. (1987) [Pubmed]
  26. Ethosuximide pharmacokinetics in a pregnant patient and her newborn. Koup, J.R., Rose, J.Q., Cohen, M.E. Epilepsia (1978) [Pubmed]
  27. Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration. Patel, I.H., Levy, R.H., Bauer, T.G. Epilepsia (1975) [Pubmed]
  28. Gamma hydroxybutyrate in the monkey. II. Effect of chronic oral anticonvulsant drugs. Snead, O.C. Neurology (1978) [Pubmed]
  29. Simultaneous very fast liquid-chromatographic analysis of ethosuximide, primidone, phenobarbital, phenytoin, and carbamazepine in serum. Kabra, P.M., Nelson, M.A., Marton, L.J. Clin. Chem. (1983) [Pubmed]
  30. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Liu, H., Delgado, M.R. Clinical pharmacokinetics. (1999) [Pubmed]
  31. Antiepileptic agents affect hypothalamic beta-endorphin concentrations. Martini, A., Sacerdote, P., Mantegazza, P., Panerai, A.E. J. Neurochem. (1984) [Pubmed]
  32. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Bachmann, K., He, Y., Sarver, J.G., Peng, N. Xenobiotica (2003) [Pubmed]
  33. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Bachmann, K.A., Jauregui, L. Xenobiotica (1993) [Pubmed]
  34. Pharmacological profiles of generalized absence seizures in lethargic, stargazer and gamma-hydroxybutyrate-treated model mice. Aizawa, M., Ito, Y., Fukuda, H. Neurosci. Res. (1997) [Pubmed]
  35. Simplified gas chromatography of valproic acid and ethosuximide. Manfredi, C., Zinterhofer, L. Clin. Chem. (1982) [Pubmed]
  36. Simultaneous measurement of phenobarbital, phenytoin, primidone, ethosuximide, and carbamazepine in serum by high-pressure liquid chromatography. Kabra, P.M., Stafford, B.E., Marton, L.J. Clin. Chem. (1977) [Pubmed]
  37. Substrate-labeled fluorescent immunoassay for ethosuximide evaluated. Walker, S.M., Hill, R.E. Clin. Chem. (1983) [Pubmed]
WikiGenes - Universities